World's Best Scientists 2026 revealed!
Mary-Ellen Taplin

Mary-Ellen Taplin

Mary-Ellen Taplin publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mary-Ellen Taplin sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

The last bar groups every scientist with 1,796 publications or more.

Mary-Ellen Taplin D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mary-Ellen Taplin sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

The last bar groups every scientist with 217 D-Index or more.

Overview

Mary-Ellen Taplin is affiliated with Harvard University in the United States and specializes in research spanning medicine and biochemistry, genetics, and molecular biology. Their work predominantly focuses on prostate cancer treatment and research, covering aspects such as diagnosis, treatment, cancer genomics and diagnostics, as well as cancer metabolism and genetics.

Their main research topics include:

  • Prostate Cancer Treatment and Research
  • Prostate Cancer Diagnosis and Treatment
  • Cancer, Lipids, and Metabolism
  • Cancer Genomics and Diagnostics
  • BRCA gene mutations in cancer
  • Bladder and Urothelial Cancer Treatments
  • Estrogen and related hormone effects

Mary-Ellen Taplin's research is categorized within the subfields of pulmonary and respiratory medicine, cancer research, genetics, surgery, and oncology.

Frequent publication venues for this researcher include:

  • Journal of Clinical Oncology
  • European Urology
  • Cancer Cell
  • JCO Oncology Practice
  • Clinical Cancer Research

Some of the recent papers authored or coauthored by Mary-Ellen Taplin are:

  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019, 2020, European Urology
  • Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019, 2020, Journal of Clinical Oncology
  • Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer, 2020, Cancer Cell
  • Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update, 2021, Journal of Clinical Oncology
  • Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer, 2020, Journal of Clinical Oncology

Collaborations are a significant aspect of their work, with frequent co-authors including Himisha Beltran, Alicia K. Morgans, Martin Gleave, Susan Halabi, and Charles J. Ryan.

Best Publications

  • Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

    Howard I. Scher;Karim Fizazi;Fred Saad;Mary-Ellen Taplin

  • Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

    Daniel P. Petrylak;Catherine M. Tangen;Maha H.A. Hussain;Primo N. Lara

  • Integrative clinical genomics of advanced prostate cancer

    Dan Robinson;Eliezer M. Van Allen;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz

  • Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

    Tomasz M Beer;Andrew J Armstrong;Dana E Rathkopf;Yohann Loriot

  • Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Charles J. Ryan;Matthew R. Smith;Johann S. De Bono;Arturo Molina

  • Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

    Mary-Ellen Taplin;Glenn J. Bubley;Todd D. Shuster;Martha E. Frantz

  • Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

    Colin C. Pritchard;Joaquin Mateo;Michael F. Walsh;Navonil De Sarkar

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

    Howard I Scher;Tomasz M Beer;Celestia S Higano;Aseem Anand

  • Genomic correlates of clinical outcome in advanced prostate cancer.

    Wassim Abida;Joanna Cyrta;Joanna Cyrta;Glenn Heller;Davide Prandi

  • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Charles J. Ryan;Matthew R. Smith;Karim Fizazi;Fred Saad

  • Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options

    Martin G. Sanda;Jeffrey A. Cadeddu;Erin Kirkby;Ronald C. Chen

  • Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors

    Viktor A. Adalsteinsson;Viktor A. Adalsteinsson;Gavin Ha;Gavin Ha;Samuel S. Freeman;Samuel S. Freeman;Atish D. Choudhury

  • Selection for Androgen Receptor Mutations in Prostate Cancers Treated with Androgen Antagonist

    Mary-Ellen Taplin;Glenn J. Bubley;Yoo-Joung Ko;Eric J. Small

  • The long tail of oncogenic drivers in prostate cancer

    Joshua Armenia;Stephanie A. M. Wankowicz;Stephanie A. M. Wankowicz;David Liu;David Liu;Jianjiong Gao

  • Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline

    D. Andrew Loblaw;Katherine S. Virgo;Robert Nam;Mark R. Somerfield

  • Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer

    Jens G. Lohr;Jens G. Lohr;Viktor A. Adalsteinsson;Viktor A. Adalsteinsson;Kristian Cibulskis;Atish D. Choudhury;Atish D. Choudhury

  • Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence

    Mary-Ellen Taplin;Steven P. Balk

  • Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663

    Mary-Ellen Taplin;Barur Rajeshkumar;Susan Halabi;Cary P. Werner

  • Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer

    Daniel C. Danila;Michael J. Morris;Johann S. De Bono;Charles J. Ryan

Frequent Co-Authors

Philip W. Kantoff
Philip W. Kantoff Memorial Sloan Kettering Cancer Center
Eliezer M. Van Allen
Eliezer M. Van Allen Harvard University
Steven P. Balk
Steven P. Balk Beth Israel Deaconess Medical Center
Peter S. Nelson
Peter S. Nelson Fred Hutchinson Cancer Research Center
Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Christopher Sweeney
Christopher Sweeney Harvard University
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Eric J. Small
Eric J. Small University of California, San Francisco
William Oh
William Oh Icahn School of Medicine at Mount Sinai
Toni K. Choueiri
Toni K. Choueiri Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA goes beyond becoming a traditional physician. There are numerous flexible, accredited online programs for those interested in healthcare careers. For nurses aiming to move into advanced practice or leadership roles, the best online bsn to dnp programs offer comprehensive training with the convenience of remote learning.

Pharmacy is another area seeing strong online options. Aspiring pharmacists can find reputable online pharmacy programs that prepare them for licensure and clinical practice—perfect for those needing to balance study with other commitments.

For students interested in the administrative side of medicine, consider a health information management degree online. These programs train professionals to securely organize, analyze, and manage patient data, a vital part of modern healthcare systems.

Finally, if you prefer shorter programs or entry-level roles, medical billing and coding online courses cost less time and money to complete. They allow you to quickly gain skills for in-demand jobs supporting hospitals and clinics across the country.

Best Scientists Citing Mary-Ellen Taplin

Trending Scientists

Recently Published Articles